Clinical trials
Phase 2 Carcinoma in Situ trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
7 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2013 | 1 |
| 2017 | 1 |
| 2020 | 1 |
| 2023 | 1 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 3 |
| Completed | 2 |
| Terminated | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| CG Oncology, Inc. | 1 |
| H. Lee Moffitt Cancer Center and Research Institute | 1 |
| Merck Sharp & Dohme LLC | 1 |
| Michael A. O'Donnell | 1 |
| Protara Therapeutics | 1 |
| Telormedix SA | 1 |
| University of Pittsburgh | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carcinoma in Situ | 7 |
| Non-Muscle Invasive Bladder Neoplasms | 5 |
| Urinary Bladder Neoplasms | 5 |
| Carcinoma, Non-Small-Cell Lung | 1 |
| Carcinoma, Transitional Cell | 1 |
| Pulmonary Disease, Chronic Obstructive | 1 |
| Urinary Bladder Diseases | 1 |
Trials
Showing 1 to 7 of 7. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.